Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > This reads like a John Grisham novel
View:
Post by BloombergReel on Feb 15, 2021 5:52am

This reads like a John Grisham novel

Comment by 99942Apophis on Feb 15, 2021 7:12am
That is so revealing of how large financial institutions are interwoven its frightening, thank you BloombergReel, I think I will buy gold bars and bury them in my backyard beside the Maple tree and get out of the stock market.
Comment by fredgoodwinson on Feb 15, 2021 7:36am
Understand from this that as a nominee shareholder I don`t actually own ‘my’ shares for the purposes of shorting - the Brokers do.   Could go a long way to explaining some of the baffling trading patterns in TLT over the years
Comment by StevenBirch on Feb 15, 2021 8:08am
It seems like basher lawsuits and shorting have replaced politics as the new distraction and by newly created accounts. 
Comment by Impalaman on Feb 15, 2021 8:22am
Your not the only one steve--- that has noticed all the new names----it all started with the NUT that posted about the 36 people that are on death row----strange that they are all poppin up ----right after fridays stock runup------Has the OSC---got the hornets angry---are the shorts starting to cover---HHHHUUUUMMMMMM.
Comment by robertshaw on Feb 15, 2021 11:23am
Agree, Newly created account as new Blowjobjoe.
Comment by SamRothstein on Feb 15, 2021 11:30am
Exactly.  Let the criminals take their sophomoric potshots.  We will not be deterred. When you are on the right side of the law and of morality victory is assured.  
Comment by winr88 on Feb 16, 2021 11:22am
If you ever do that, make sure you add some silver too. LOL
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250